Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 2/20 | 0.32 |
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL259634 | 0.81 | MAPT (0.37) | MAPTALDH1A1KDM4EMAPK1SMN1; SMN2 | |
| SCHEMBL258758 | 0.79 | ESR1 (0.34) | POLBCNR2GPR55ALDH1A1KDM4E | |
| SCHEMBL20906372 | 0.75 | ATP4A (0.34) | CNR2GPR55CNR1MAPTALDH1A1 | |
| SCHEMBL31566365 | 0.74 | CYP3A4 (0.35) | POLBALDH1A1KDM4EMAPK1SMN1; SMN2 | |
| SCHEMBL31566366 | 0.74 | CYP3A4 (0.35) | POLBALDH1A1KDM4EMAPK1SMN1; SMN2 | |
| SCHEMBL301210 | 0.74 | CYP3A4 (0.35) | POLBALDH1A1KDM4EMAPK1SMN1; SMN2 | |
| SCHEMBL4885181 | 0.70 | ACHE (0.38) | MAPTALDH1A1 | |
| SCHEMBL10259028 | 0.70 | ACHE (0.38) | MAPTALDH1A1 | |
| SCHEMBL20906761 | 0.70 | KDM4E (0.31) | POLBCNR2GPR55ALDH1A1KDM4E | |
| SCHEMBL20021638 | 0.70 | CA1 (0.38) | POLBMAPTALDH1A1KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067642-B2 | Chiral phosphorous compounds | Celtice Catalysts Limited, Nova UCD (IE) | 2011-11-29 | — | — | US | disclosed |
| US-8067642-B2 | Chiral phosphorous compounds | Celtice Catalysts Limited, Nova UCD (IE) | 2011-11-29 | — | — | US | disclosed |
| US-20100168456-A1 | CHIRAL PHOSPHOROUS COMPOUNDS | CELTIC CATALYSTS LIMITED (IE) | 2010-07-01 | — | — | US | disclosed |
| US-20100168456-A1 | CHIRAL PHOSPHOROUS COMPOUNDS | CELTIC CATALYSTS LIMITED (IE) | 2010-07-01 | — | — | US | disclosed |
| WO-2008117054-A2 | CHIRAL DIPHOSPHINES, METHODS FOR THEIR PREPARATION, TRANSITION METAL COMPLEXES COMPRISING THEM AND USE IN CHIRAL SYNTHESIS | CELTIC CATALYSTS LIMITED (IE) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168456-A1 | CHIRAL PHOSPHOROUS COMPOUNDS | RPP30, PLCB3, INPP5D | POLB 3136/4885CNR2 1324/4885GPR55 1222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.